MapLight’s $251m IPO sees schizophrenia drug developers on top

MapLight Therapeutics aims to raise around $251m via an initial public offering (IPO), a figure that would propel the biotech to the upper echelons of the sector’s public listing value so far in 2025. Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech will trade on the Nasdaq Global Market under the symbol "MPLT." In terms of timings, MapLight has used a regu ...